Drugs / CD19.22.BBζ
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03448393 | Mar 2018 → Jul 2024 | B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19.22.BBζ | “Our initial experience with a bivalent CD19.22.BBζ CAR T-cell construct in children, adolescents and young adults (CAYA) with B-cell acute lymphoblastic leukemia (B-ALL)...” PMID 42248607 ↗ Jun 2026 |
| Modality | Cell therapy | “modified CD19/CD22-CAR T cells” NCT03448393 ↗ |
| Route | Intravenous | “Their changed cells by IV” NCT03448393 ↗ |